Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Antidepressant‐like effects of BU10119, a novel buprenorphine analogue with mixed κ/μ receptor antagonist properties, in mice
Abdulrahman Almatroudi, Mehrnoosh Ostovar, Christopher Bailey, et al.
British Journal of Pharmacology (2017) Vol. 175, Iss. 14, pp. 2869-2880
Open Access | Times Cited: 23

Showing 23 citing articles:

Targeting opioid dysregulation in depression for the development of novel therapeutics
Caroline A. Browne, Irwin Lucki
Pharmacology & Therapeutics (2019) Vol. 201, pp. 51-76
Open Access | Times Cited: 84
Kappa Opioid Receptor Antagonists as Potential Therapeutics for Stress-Related Disorders
Moriah L. Jacobson, Caroline A. Browne, Irwin Lucki
The Annual Review of Pharmacology and Toxicology (2020) Vol. 60, Iss. 1, pp. 615-636
Closed Access | Times Cited: 56
In Vitro Pharmacological Characterization of Buprenorphine, Samidorphan, and Combinations Being Developed as an Adjunctive Treatment of Major Depressive Disorder
Jean M. Bidlack, Brian I. Knapp, Daniel R. Deaver, et al.
Journal of Pharmacology and Experimental Therapeutics (2018) Vol. 367, Iss. 2, pp. 267-281
Open Access | Times Cited: 57
Buprenorphine as a Treatment for Major Depression and Opioid Use Disorder
Amanda B. Namchuk, Irwin Lucki, Caroline A. Browne
Advances in Drug and Alcohol Research (2022) Vol. 2
Open Access | Times Cited: 22
Bifunctional opioid receptor ligands as novel analgesics
Christopher W. Cunningham, Waleed M. Elballa, Stephanie U. Vold
Neuropharmacology (2019) Vol. 151, pp. 195-207
Closed Access | Times Cited: 42
Endogenous Opiates and Behavior: 2018
Richard J. Bodnar
Peptides (2020) Vol. 132, pp. 170348-170348
Closed Access | Times Cited: 21
Antidepressant-like effect of tofisopam in mice: A behavioural, molecular docking and MD simulation study
Nazlı Turan Yücel, Asaf Evrim Evren, Ümmühan Kandemir, et al.
Journal of Psychopharmacology (2022) Vol. 36, Iss. 7, pp. 819-835
Closed Access | Times Cited: 13
SLL-627 Is a Highly Selective and Potent κ Opioid Receptor (KOR) Agonist with an Unexpected Nonreduction in Locomotor Activity
Linghui Kong, Xuelian Shu, Siyuan Tang, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 15, pp. 10377-10392
Closed Access | Times Cited: 11
Targeting opioid receptor signaling in depression: do we need selective κ opioid receptor antagonists?
Sarah Bailey, Stephen M. Husbands
Neuronal Signaling (2018) Vol. 2, Iss. 2
Open Access | Times Cited: 16
Translational value of non-human primates in opioid research
Huiping Ding, Mei‐Chuan Ko
Experimental Neurology (2021) Vol. 338, pp. 113602-113602
Open Access | Times Cited: 12
Diels–Alder Adducts of Morphinan-6,8-Dienes and Their Transformations
János Marton, Anikó Fekete, Paul Cumming, et al.
Molecules (2022) Vol. 27, Iss. 9, pp. 2863-2863
Open Access | Times Cited: 8
OREX-1019: A Novel Treatment of Opioid Use Disorder and Relapse Prevention
David R. Maguire, Lisa R. Gerak, Gerta Cami‐Kobeci, et al.
Journal of Pharmacology and Experimental Therapeutics (2019) Vol. 372, Iss. 2, pp. 205-215
Open Access | Times Cited: 12
The Association Between Self-Reported Anxiety and Retention in Opioid Agonist Therapy: Findings From a Canadian Pragmatic Trial
Anees Bahji, Gabriel Bastien, Paxton Bach, et al.
The Canadian Journal of Psychiatry (2023) Vol. 69, Iss. 3, pp. 172-182
Open Access | Times Cited: 4
Historical perspectives and recent advances in small molecule ligands of selective/biased/multi-targeted μ/δ/κ opioid receptor (2019–2022)
Ye He, Qian Peter Su, Liyun Zhao, et al.
Bioorganic Chemistry (2023) Vol. 141, pp. 106869-106869
Closed Access | Times Cited: 4
The Buprenorphine Analogue BU10119 Attenuates Drug-Primed and Stress-Induced Cocaine Reinstatement in Mice
Todd M. Hillhouse, Keith M. Olson, James E. Hallahan, et al.
Journal of Pharmacology and Experimental Therapeutics (2021) Vol. 378, Iss. 3, pp. 287-299
Open Access | Times Cited: 10
In vitro and in vivo activity of cyclopeptide Dmt-c[ d -Lys-Phe-Asp]NH 2 , a mu opioid receptor agonist biased toward β-arrestin
Katarzyna Gach, Justyna Piekielna‐Ciesielska, Anna Adamska‐Bartłomiejczyk, et al.
Peptides (2018) Vol. 105, pp. 51-57
Closed Access | Times Cited: 11
Biased Agonism as an Emerging Strategy in the Search for Better Opioid Analgesics
Justyna Piekielna‐Ciesielska, Karol Wtorek, Anna Janecka
Current Medicinal Chemistry (2019) Vol. 27, Iss. 9, pp. 1562-1575
Closed Access | Times Cited: 10
Modulation of the central opioid system as an antidepressant target in rodent models
K. McHugh, John Kelly
Progress in brain research (2018), pp. 49-87
Closed Access | Times Cited: 8
Classics in Chemical Neuroscience: Buprenorphine
Jillian L. Kyzer, Cody J. Wenthur
ACS Chemical Neuroscience (2020) Vol. 11, Iss. 10, pp. 1385-1399
Closed Access | Times Cited: 6
Uncovering kappa-opioid receptor agonist-induced PAK1/2 phosphorylation by quantitative phosphoproteomics
Jian Wu, Qinghui Jiang, Hongwen Zhu, et al.
Biochemical and Biophysical Research Communications (2019) Vol. 516, Iss. 1, pp. 320-326
Closed Access | Times Cited: 5
The aetiology of social deficits within mental health disorders: The role of the immune system and endogenous opioids
Sarah Jane Charles, Miguel Farias, R. I. M. Dunbar
Brain Behavior & Immunity - Health (2019) Vol. 1, pp. 100003-100003
Open Access | Times Cited: 4
Emerging areas of opioid pharmacology
Eamonn Kelly, Graeme Henderson, Christopher Bailey
British Journal of Pharmacology (2018) Vol. 175, Iss. 14, pp. 2715-2716
Open Access | Times Cited: 3
Insights into the Neurobiology of Anxiety and a Potential Target for Pharmacotherapy
Rami Hamati
Journal of Neuroscience (2018) Vol. 38, Iss. 42, pp. 8919-8921
Open Access | Times Cited: 3
Page 1

Scroll to top